Blurbs

Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN), 9 Meters Biopharma (NMTR) and TCR2 Therapeutics (TCRR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ocugen (OCGNResearch Report), 9 Meters Biopharma (NMTRResearch Report) and TCR2 Therapeutics (TCRRResearch Report).

Ocugen (OCGN)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Ocugen today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.94, close to its 52-week low of $1.67.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.8% and a 30.8% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocugen with a $8.67 average price target.

See today’s best-performing stocks on TipRanks >>

9 Meters Biopharma (NMTR)

Maxim Group analyst Naz Rahman maintained a Hold rating on 9 Meters Biopharma yesterday. The company’s shares closed last Wednesday at $0.22, close to its 52-week low of $0.20.

According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.2% and a 16.2% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Processa Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for 9 Meters Biopharma with a $3.67 average price target.

TCR2 Therapeutics (TCRR)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on TCR2 Therapeutics, with a price target of $20.00. The company’s shares closed last Wednesday at $1.85, close to its 52-week low of $1.69.

According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.9% and a 31.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

TCR2 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos